natgillin/translations-raw huggingface dataset:
The torque tubes 102 are provided one at each end of the ball screw 48, and are each connected to the housing 20 so that they cannot rotate. 
Po jedna momentna cijev se nalazi na svakom kraju kuglastog vijka (48), i svaka je spojena na kućište (20) tako da se ne može zakretati.
In an embodiment inclination of the downward aligned edge is less than the inclination of at least an upper part of the upward flank, as result of which an expansion chamber will be formed between both surface which will be favorable to allow play and to compensate expansion, e.g. due to moist absorption by the floor panels. 
Podni panel (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od prethodno navedenih zahtjeva, naznačen time da je nagib prema dolje poravnatog ruba manji od nagiba najmanje gornjeg dijela (42b) gornjeg boka (26, 42,
Such liquids can be used for the described process, i.e. as filling medium, as well. 
Takove tekućine se mogu upotrijebiti za opisani postupak, tj. također kao punilo.
In another preferred embodiment, the content of the pharmacologically active agent according to the general formula (I) in the pharmaceutical dosage form according to the invention is within the range of 0.4±0.3 wt.-%, for example, 0.4±0.2 wt.-%, or even 0.4±0.1 wt.-%. 
Farmaceutski oblik doziranja za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što farmakološki aktivno sredstvo prema općoj formuli (I) ima stereokemiju prema općoj formuli (T) pri čemu je R definiran kao u patentnom zahtjevu 1.
The compound of claim 1, wherein M is H. 
Spoj sukladno patentnom zahtjevu 1, naznačeno time, što M je H.
Whereas the lines in Figure 7 are all similar shapes to each other, however, the most diluted sample gave very different results (Figure 8). 
Nasuprot tome linije na Slici 7 su sve sličnih oblika jedna prema drugoj, međutim, najviše razrijeđeni uzorak dao je vrlo različite rezultate (Slika 8).
After 4 hours LCMS indicated the product had formed. 
Nakon 4 sata je LCMS pokazao daje proizvod formiran.
When possible, glass fiber materials having a low softening point, e.g., below about 650°C, are preferred. 
Kada je to moguće poželjni su materijali od staklenih vlakana koji imaju nisku točku omekšavanja, n.pr., ispod oko 650"C.
A dietary chocolate composition containing erythrol at 1-40% by weight, inulin at 1-75% by weight and a sweetener mixture with reduced calorie and low glycemic index, characterized in that the said composition further comprises, 
Pripravak za dijetnu čokoladu koji se sastoji od eritrola u količini od 1 - 40 težinskih %, inulina u količini od 1 - 75 težinskih % i smjese za zaslađivanje s reduciranim kalorijama 1 glikemičkim indeksom, naznačen time što nadalje sadrži
The acylthiourea compound according to claim 1 or a salt thereof, wherein R1 is a hydrogen atom or a methyl group; R2 is an optionally substituted C1-6 alkyl group, an optionally substituted phenyl group, or an optionally substituted 5- to 7-membered heterocyclic group which has 1 or 2 nitrogen atom(s) or sulfur atom(s), or R1 and R2 form, together with the nitrogen atom to which they are attached, an optionally substituted pyrrolidinyl group or an optionally substituted piperidinyl group; R3 is a methyl group; R4 is a fluorine atom or a chlorine atom; R5 is a hydrogen atom or a halogen atom; and R6 is a hydrogen atom, a halogen atom, a trifluoromethyl group or a methoxy group. 
je po izboru supstituirana C1-6 alkil skupina, po izboru supstituirana fenil skupina, ili po izboru supstituirana 5- do 7- člane heterociklička skupina koja ima 1 ili 2 atoma dušika ili atom(e) sumpora, ili R1 i R2 oblik, zajedno s atomom dušika na kojeg su vezani, po izboru supstituiranu pirolidinil skupinu ili po izboru supstituiranu piperidinil skupinu; je metil skupina, je atom fluora ili atom klora,
The C1-2 perhalogenated alkyl group represents an alkyl group wherein all of the hydrogens have been substituted by halogens, for example a CF3 or C2F5; 
Perhalogenirana C,.> alkilna skupina predstavlja alkilnu skupinu gdje su svi vodici zamijenjeni halogenima, primjerice CF; ili CoFs.
Said embodiment is characterized in that boards of wood 10 were glued to a beam-like block of wood 12 in the manner of a herringbone pattern - as shown in Fig. 8 and 9. 
Navedeno ostvarenje je karakteristično po tome što su ploče od drva 10 bile zalijepljene na blok od drva koji ima oblik grede 12 na takav način da se dobije uzorak kosti od haringe - kao što je prikazano na slikama 8 i 9.
A modified serpin according to any one of claims 1 to 11 comprising an amino acid sequence having at least 70% sequence identity to residues 25-418 of SEQ ID NO: 12, wherein the P4 residue in the RCL of the modified serpin is A, the P2 residue is K, P1 residue is R and the P1' residue is K. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 11, naznačen time, da on obuhvaća aminokiselinsku sekvencu koja ima najmanje 70% identiteta sekvence prema ostatcima 25-418 od SEQ ID NO: 12, pri čemu ostatak P4 u RCL-petlji od modificiranog serpina je A, ostatak P2 je K, ostatak P1 je R i ostatak P1' je Ki.
N -Hydroxy-2-phenyl benzene sulfonamide; and pharmaceutically acceptable salts thereof. 
N-Hidroksi-2-fenil benzen sulfonamid; i njihove farmaceutski prihvatljive soli.
A few embodiments of an assembly according to the invention will be explained in more detail with reference to the appended drawing. 
Nekoliko izvedbi sklopa u skladu s izumom će biti detaljnije objašnjeno uz pozivanje na priložene crteže.
Mannitol-estetrol (10:1) granulate 
(10) Identifikator
R16A and R16B are each independently selected from H and an optionally substituted C1-C8 alkyl, or together with the nitrogen to which they are attached form an optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
R'* i R!'" su svaki nezavisno odabrani od H i proizvoljno supstituirani C,-Ca alkil, ili zajedno s atomom dušika za kojega je vezan formira proizvoljno supstituiran hetero Cx-C;g Cikloalkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R'" skupine;
at least 24% of the cells in the population express detectable levels of CD99, 
(vi) najmanje 24 % stanica u populaciji na svojoj površini izražava uočljive razine CD99,
According to one embodiment of the invention the PDE4 inhibitor is roflumilast. 
Prema jednom utjelovljenju predmetnog izuma B2-agonist je formoterol, osobito formoterol fumarat.
The method according to claim 1, wherein said intervertebral disc-related pain is selected from neck pain, chronic neck pain, low back pain, and chronic low back pain. 
Kompozicija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačena time što je navedena bol povezana s intervertebralnim diskom odabrana od boli u vratu, kronične boli u vratu, boli u donjem dijelu leđa i kronične boli u donjem dijelu leđa.
Pull-out mechanism according to one or more of claims 1-4 characterised in that the intermediate rail (10; 10': 10") has a cross-section substantially corresponding to an I, and that the intermediate rail is preferably manufactured by bending of a metal sheet, especially such that each of the webs of the intermediate rail includes two layers of metal sheets. 
Mehanizam za izvlačenje ladice u skladu s jednim ili s više patentnih zahtjeva 1 do 4, naznačen time što među- tračnica (10; 10%; 10%) ima poprečni presjek koji uglavnom odgovara obliku slova I, 1 što je poželjno da je među- tračnica proizvedena savijanjem metalnog lima, naročito na takav način da svaka od staza među-tračnice ima dva sloja metalnog lima.
in part (e), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:121 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:120; 
(e) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 117i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 116;
The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition is for oral, parenteral, intramuscular or topical administration, and is in the form of a tablet, capsule, sachet, injectable preparat, suspension, syrup, gel, cream or ointment. 
Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je navedeni farmaceutski pripravak pogodan za oralnu, parenteralnu, intramuskularnu ili topičku administraciju, te kao takav dolazi u obliku tablete, kapsule, kao prah u vrećici, injektibilnog preparata, suspenzije, sirupa, gela, kreme, pomade.
A pharmaceutical comprising one or more compounds of the formula I as claimed in one or more of claims 1 to 4 and one or more active substances which have favorable effects on metabolic disturbances or disorders frequently associated therewith. 
Farmaceutski pripravak koji sadrži jedan ili više spojeva formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23 ijednu ili više aktivnih tvari koje povoljno djeluju na metaboličke poremećaje ili na poremećaje koji su često s njima povezani.
An inhaler according to any one of claims 7 to 10 wherein Compound (I) and Compound (II) are presented in a form adapted for simultaneous administration. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s patentnim zahtjevom 10, naznačena time što se Spoj (1) i Spoj (II) daje u obliku prilagođenom za istodobnu primjenu. s
The single-handle dual-control thermostatic faucet according to any preceding claim, wherein a hot water feed pipe and a cold water feed pipe are included, both of which are respectively connected to the hot water and cold water inlets of the valve body. 
Termostatska slavina s jednom ručkom i dvojnom kontrolom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su uključene cijev za dovod vruće vode (41) 1 cijev za dovod hladne vode (42), od kojih su obje odgovarajuće povezane s ulazom vruće vode i ulazom hladne vode (81, 82) na tijelu ventila.
A composition comprising the conditional replication defective CMV of any of claims 1-10 and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži imunološki efikasnu količinu CMYV s uvjetno defektnom replikacijom prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač.
The method of claim 9, wherein the thioester precursor is furfurylthioacetate, methylthioacetate, prenylthioacetate or a mixture thereof. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je tioesterski preteča furfuril-tioacetat, metil-tioacetat, prenil-tioacetat ili njihova smjesa.
The solid support of claim 12, wherein the second polynucleotide is hybridized to the 3′ end of the first polynucleotide, and the first polynucleotide is immobilized at its 5′ end to the surface of the solid support. 
te gdje su transposomski kompleksi homodimeri, gdje homodimeri koji sadrže prvo mnoštvo homodimera koji sadrže prvi polinukleotid prvog slijeda i drugo mnoštvo homodimera koji sadrže prvi polinukleotid drugog slijeda.
A dihydroazole compound of formula (I), or a pharmaceutically or agriculturally acceptable salt thereof: wherein: 
spoj dihidroazola formule (I), ili njegovu veterinarski ili agrikulturno prihvatljivu sol:
Coating of bitter drugs is another method which has been reported for taste masking. 
Oblaganje gorkih lijekova je slijedeći postupak za maskiranje okusa.
The process according to claim 36, characterised in that the additional treatment agent is a siloxane, and more preferably is a polydimethylsiloxane (PDMS). 
Postupak prema zahtjevu 23, naznačen time da je dodatno sredstvo za obradu siloksan, te poželjnije polidimetilsiloksan (PDMS).
It is also disclosed that the water soluble species comprise charged species and neutral species and the ratio by weight of the total amount of charged species to the total amount of neutral species in the soaking liquid may be in a range selected from the group consisting of 20:100 to 90:100, 40:100 to 80:100, and 50:100 to 80:100. 
Proces iz patentnog zahtjeva 5, gdje u vodi topljive vrste sadrže naelektrizirane vrste i neutralne vrste i odnos po masi ukupne količine naelektrizirane vrsta prema ukupnoj količini neutralnih vrsta u tekućini za natapanje je u opsegu odabranom iz grupe koja se sastoji od 20:100 do 90:100, 40:100 do 80:100, 1 50:100 do 80:100.
Use, in combination, of a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, for producing a cancer chemotherapeutic agent. 
Upotreba, u kombinaciji, derivata kolestanola, naznačena time, da je predstavljen formulom (1): [image] (pri čemu G predstavlja GlcNAc- ili GlcNAc-Gal-) ili njihov inkluzijski spoj ciklodekstrina, i irinotekan kao protutumorsko sredstvo.
The system of claim 1, wherein the mobile suction means is operatively coupled to the propelling means by a rigid rod, bar, pole, shaft, or a combination thereof. 
Sustav prema bilo kojem od zahtjeva 1-3, naznačen time što spojna sredstva (5) obuhvaćaju krutu šipku, šipku, stup, osovinu ili njihovu kombinaciju.
The compound of any one of claims 1-4 wherein the hematological cancer is leukemia, preferably selected from acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative disorder/neoplasm and myelodysplastic syndrome, and further preferably wherein the leukemia is human acute myeloid leukemia. 
Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-12, pri čemu je malignitet leukemija. Tvar za uporabu u skladu s patentnim zahtjevom 13, pri čemu je leukemija odabrana između akutne limfocitne leukemije, kronične limfocitne leukemije, kronične mijeloične leukemije, mijeloproliferativnog poremećaja/neoplazme i mijelodisplastičnog sindroma.
The composition of claim 1 or 7, wherein at least two different antibodies in the mixture are IgG antibodies. 
Farmaceutski spoj koji sadrži najmanje dva različita antitijela u skladu s patentnim zahtjevom 13 i farmaceutski prihvatljiv nosač.
The nonwoven according to claim 1, wherein the opposite faces of the nonwoven are opposite exterior faces of the nonwoven, and the nonwoven is a single ply nonwoven. 
Netkani materijal prema zahtjevu 1, naznačen time da nasuprotna lica netkanog materijala predstavljaju nasuprotna vanjska lica netkanog materijala, a netkani materijal je jednoslojni netkani materijal.
These examples, namely 
Ovi primjeri, naime
The method according to claim 1, wherein the superheated steam's temperature and the exhaust steam's temperature leaving the at least one drying chamber differs by a temperature difference ATR, wherein the excess steam's saturated temperature and the compressed excess steam's saturated temperature differs by a temperature difference ATE, and wherein the difference between ATE and ATR is from 4 to 20° C. 
Postupak u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da se temperatura vruće pare (6) i temperatura ispušne pare (3) koja izlazi iz barem jedne komore za sušenje razlikuje temperaturnom razlikom ATR, pri čemu je ATRod 5 do 100°C, poželjno od 10 do 50°C, poželjnije od 15 do 30°C, još poželjnije od 15 do 25°C i najpoželjnije oko 22°C.
The mixture was washed with saturated sodium bicarbonate solution, water, and brine, dried over sodium sulfate, and concentrated in vacuo. 
Smjesa se ispere zasićenom otopinom natrijevog bikarbonata, vodom i soli, suši na natrijevom sulfatu, i koncentrira uz podtlak.
Toilet basket according to claim 1, wherein the one or more inlet openings are in the shape of a slit. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da je element za distribuciju vode za ispiranje (8) oblikovan integralno sa spremnikom ili spremnicima.
The process according to claim 21, characterized in that said organic material in an aqueous medium is selected from the group comprising petroleum, petroleum derivatives, styrene-butadiene binders, latex, rubber, vinyl acrylates, polyisoprene, polybutadiene, hot melts, pitch or mixtures thereof, said pitch being preferably non-ionic and/or anionic. 
Postupak prema zahtjevu 21, naznačen time da je navedeni organski materijal u vodenom mediju odabran iz skupine koja sadrži naftu, naftne derivate, ljepljive kontaminante, nečistoće ili njihove smjese, te su navedene nečistoće poželjno neionske i/ili anionske.
The method according to claim 17, wherein the at least one additional active agent is formoterol fumarate in an amount ranging from about 5 micrograms to 25 micrograms per metered nominal dose. The method according to claim 17, wherein the at least one additional active agent is mometasone furoate in an amount ranging from about 100 micrograms to 900 micrograms per metered nominal dose. The method of claim 15, wherein the dose is a twice-daily dose of a) a metered nominal dose of aclidinium equivalent to 400 micrograms plus/minus 10% of aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 14, naznačen time, što je (a) dodatna aktivna tvar formoterol fumarat u količini od 5-25 ug po dozi ili je (b) dodatna aktivna tvar formoterol fumarat u količini od 6 ug po dozi ili je (c) dodatna aktivna tvar formoterol fumarat u količini od 12 ug po dozi. Primjena aklidinija u slobodnom obliku ili u obliku farmaceutski prihvatljive soli u proizvodnji lijeka za liječenje kronične opstruktivne plućne bolesti u bolesnika kojem je potrebno takvo liječenje, pri čemu se spomenuta primjena sastoji od davanja inhalacijom jednom ili dvaput dnevno odmjerene nominalne doze aklidinija jednake 400 mikrograma (plus/minus 10 %) aklidinijevog bromida.
The gaming and/or entertainment device as claimed in claim 1, wherein the touch panel forms a transparent viewing panel which is mounted in front of the display units and which is fitted into a device housing and forms a front region of the device housing facing the device operating position. The gaming and/or entertainment device as claimed in claim 1, wherein the touch panel extends over at least 30% of the surface of a housing front of the gaming and/or entertainment device facing a device operating position. 
Uređaj za igranje i/ili zabavu sukladno jednom od prethodnih zahtjeva, pri čemu dodirna ploča (25) tvori prozirnu vidljivu prednju stranu pokrova postavljenog na jedan od zaslona jedinice (12, 13, 14, 15), koje su postavljene u kućište (11) uređaja i koji tvori prednji dio kućišta uređaja okrenut prema radnom položaju uređaja, pri čemu se dodirna ploča (25) proteže preko najmanje 30 % površine kučišta ispred uređaja za igranje i/ili zabavu okrenutog prema radnom položaju.
The immunoconjugate of claim 18, wherein the linker is cleavable by a protease or is acid-labile. 
Imunokonjugat prema zahtjevu 10, naznačen time, da se poveznica može cijepati pomoću proteaze ili je kiselolabilna.
A computer program product, comprising: 
Računalni programski proizvod koji sadrži:
The population of zirconia particles is particularly useful in connection with dental filling material, see, e.g., under “Dental filling materials”. 
Populacija čestica cirkonijeva oksida je posebno korisna u svezi s materijalom za dentalna punila, vidi npr. pod "Materijali za dentalna punila".
In another embodiment, the fusion polypeptide comprises a light chain variable region and/or a heavy chain variable region of G1, as shown in SEQ ID NO:2 and SEQ ID NO:1 of FIG. 
PATENTNI ZAHTJEVI 1. - Anti-CGRP antagonističko protutijelo naznačeno time da sadrži VH domenu koja ima sekvencu aminokiselina SEQ ID NO: 1 i VL domenu koji ima sekvencu aminokiselina SEQ ID NO: 2.
According to another preferred embodiment of the process according to the present invention, the hydrophobised ground calcium carbonate and/or the hydrophobised precipitated calcium carbonate obtained in step d) is used in powder form and/or in the form of granules or in the form of slurry. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje se hidrofobizirani mljeveni kalcijev karbonat i/ili hidrofobizirani taloženi kalcijev karbonat iz koraka d) koristi u obliku praška i/ili u obliku granula ili u obliku kaše.
The solid oral extended release pharmaceutical dosage form of claim 68, wherein the opioid analgesic is oxycodone hydrochloride or hydromorphone hydrochloride and the composition comprises more than 5% (by wt) of the oxycodone hydrochloride or hydromorphone hydrochloride. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema zahtjevu 1, naznačen time da je opioidni analgetik oksikodon hidroklorid i da sastav sadrži preko 5 % (težine) oksikodon hidroklorida.
Such techniques may be applied individually or in combination. 
Takve tehnike mogu se primijeniti pojedinačno ili u kombinaciji.
billing the subscriber on the basis of the determined subscriber identification data, wherein billing includes: 
naplatu (235) navedenom pretplatniku (145) na osnovu navedenih određenih identifikacijskih podataka pretplatnika, pri čemu navedeni korak naplate obuhvaća korake koji se sastoje od:
A marking device according to claim 1, wherein said rotatable marking element (171) is arranged to apply a T-shaped or L-shaped mark on a piece of wood. 
Uređaj za označavanje prema zahtjevu 1 ili 2, naznačen time da se spomenuti rotirajući element označavanja (171) postavlja za primjenu znak u T-obliku ili L-obliku na komad drveta.
The compound according to claim 1 or claim 2, or a salt thereof, wherein R3 is 
Spoj u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, ili njegova sol, naznačen time što je R?
A pharmaceutical composition comprising 4-methyl-2-piperidin-1-yl-quinoline having the formula for use in reducing or preventing pain in a mammal by modulating TRPC4 activity, wherein the pain is selected from acute, chronic, neuropathic, nociceptive and visceral pain, or a combination thereof. 
Farmaceutski pripravak koja sadrži 4-metil-2-piperidin-1-il-kinolin koji ima formulu za uporabu u liječenju ili prevenciji bola kod sisavaca moduliranjem aktivnosti TRPC4, pri čemu je bol odabran između akutne, kronične, neuropatske, nociceptivne i visceralne boia, ili njihove kombinacije.
A solution of sodium hydroxide (3.7 g) in water (10 ml) was added to the stirring reaction mixture, followed by an aqueous solution of hydrogen peroxide (50%, ca. 7 ml) and the two-phase mixture formed was stirred at reflux for one hours. 
U miješanu reakcijsku smjesu se doda otopina natrij hidroksida (3.7 g) u vodi (10 ml) i nakon toga se doda 1 vodena otopina vodikovog peroksida (50%, oko 7 ml) te se formirana dvo-fazna smjesa miješa uz refluks tijekom jednog sata.
producing a polyethylene blend comprising from 10 wt% to 90 wt% of said recycled high density polyethylene flakes and from 90 wt% to 10 wt% of a virgin polyethylene having a multimodal or broad molecular weight distribution, with weight percentages relative to the total weight of the polyethylene blend, wherein said recycled high density polyethylene is comprising at least 50 ppm of limonene (1-methyl-4-(1-methylethenyl)-cyclohexene, CAS-nr. 
(Cc) proizvodnje polietilenske smjese koja se sastoji od 10% do 90% težinskog udjela spomenutih pahuljica Tecikliranog polietilena visoke gustoće 1 od 90% do 10% težinskog udjela nerecikliranog polietilena koji ima multimodalnu ili široku raspodjelu molekularne težine, s težinskim postocima u odnosu na ukupnu težinu polietilenske smjese, naznačeno time da spomenuti reciklirani polietilen visoke gustoće sadrži najmanje 50 ppm limonena (1-metil-4-(1- metiletenil)-cikloheksen, CAS br.
The composition according to claim 5, wherein the composition consists of: about 46 mg/ml diacetate salt of caspofungin; about 30 mg/ml sucrose and about 20 mg/ml mannitol; and 
Smjesa prema zahtjevu 6, naznačeno time da ista obuhvaća: a) oko 46 mg/ml diacetatne soli kaspofungina; b) oko 30 mg/ml sukroze i oko 20 mg/ml manitola; i c) oko 1,5 mg/ml sukcinata.